Developer docs
API playgroundTry for free, no card

Search company profiles

MoonLake Immunotherapeutics

Full company profile

uuid000035v

Namestring
MoonLake Immunotherapeutics
Legal namestring
MoonLake Immunotherapeutics AG
Websiteurl
moonlaketx.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company founded in 2021 and domiciled in Zug, Switzerland, listed on Nasdaq under ticker MLTX via De-SPAC in April 2022. The company is developing sonelokimab (SLK), a novel ~40 kDa trivalent humanized Nanobody — built from three covalently linked VHH domains — that simultaneously inhibits IL-17A/A, IL-17A/F, and IL-17F/F dimers while an albumin-binding domain enriches the molecule at sites of inflammatory edema. This mechanism, combined with the small size of the Nanobody format versus ~150 kDa traditional antibodies, is positioned to deliver deeper tissue penetration in difficult-to-reach inflamed sites. The technology platform and sonelokimab itself were in-licensed from Merck KGaA (global rights, $25M upfront plus 9.9% equity, low-teens royalties), with the underlying Nanobody IP held by Ablynx (Sanofi).

The company targets inflammatory diseases driven by IL-17 dysregulation across dermatology and rheumatology, with an active pipeline including Phase 3 VELA-1 and VELA-2 (hidradenitis suppurativa, 838 patients across 8+ countries), Phase 3 VELA-TEEN (adolescent HS), Phase 3 IZAR-1 and IZAR-2 (psoriatic arthritis), Phase 2 S-OLARIS (axial spondyloarthritis, 81% ASAS40 at Week 12), Phase 2 P-OLARIS, and Phase 2 LEDA (palmoplantar pustulosis, FDA Fast Track granted). Leadership includes former McKinsey Senior Partner Jorge Santos da Silva as CEO and Kristian Reich as Founder/CSO. The company is pre-revenue with operating losses of approximately -$267M TTM and a cash position of $357.9M-$394M as of late 2025/early 2026, supported by over $905M in cumulative funding. A BLA for sonelokimab in HS is planned for September 2026 following a positive FDA pre-BLA meeting in May 2026, with US commercial launch targeted for H2 2027 via field sales, specialty pharmacy distribution, and patient hub services supported by a Vetter Pharma manufacturing partnership.

Short descriptiontext

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab, a trivalent Nanobody that inhibits IL-17A and IL-17F, for inflammatory skin and joint diseases including hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis, with first commercial launch targeted for H2 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nanobody therapeutics, inflammatory disease treatments, IL-17 inhibitors, clinical-stage biopharmaceuticals, dermatology and rheumatology drugs
Industry3 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals for inflammatory diseases
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical-stage company. Expects first commercial launch in the United States in the second half of 2027 if sonelokimab is approved for hidradenitis suppurativa. Revenue will come from product sales of sonelokimab targeting inflammatory diseases.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1SPARK Programme
Description

Dynamic paid traineeship programme designed to give candidates hands-on experience in the biotech industry over 3 to 12 months, with opportunities in HR, Tech Ops, Medical Affairs, Clinical Operations, and other areas across Zug, Cambridge, and Porto offices.

moonlaketx.com
Core offering1 text field

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab (SLK), a novel ~40 kDa trivalent Nanobody that simultaneously inhibits IL-17A and IL-17F cytokines and binds human albumin to concentrate at inflamed tissues. The product candidate is being advanced through Phase 3 trials for hidradenitis suppurativa (VELA program) and psoriatic arthritis (IZAR program), with Phase 2 programs in palmoplantar pustulosis (LEDA, FDA Fast Track) and axial spondyloarthritis (S-OLARIS).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 67.2% HiSCR75 response rate at Week 52 in HS Phase 3 VELA trials
+6 more records
Product overview1 text field

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing a pipeline of next-level Nanobody® treatments for inflammatory diseases. The company's core product is sonelokimab (SLK), a novel ~40 kDa humanized Nanobody® targeting IL-17A and IL-17F cytokines. The therapeutic portfolio spans dermatology indications (hidradenitis suppurativa, psoriasis, palmoplantar pustulosis) and rheumatology indications (psoriatic arthritis, axial spondyloarthritis). The clinical pipeline includes multiple Phase 3 programs (VELA for HS, IZAR for PsA), Phase 2 trials (S-OLARIS for axSpA, LEDA for PPP), and Phase 3 ready development for psoriasis. The Nanobody® platform technology enables enhanced tissue penetration and targeted inhibition of inflammatory pathways compared to traditional antibodies.

Product and service1 record
1Sonelokimab (SLK / M1095 / ALX-0761)
CategoryBiologic drug candidate (Nanobody / IL-17A/F inhibitor)
Description

Novel ~40 kDa humanized trivalent Nanobody therapeutic candidate that selectively binds IL-17A and IL-17F (inhibiting IL-17A/A, IL-17A/F and IL-17F/F dimers) and human serum albumin, intended for the treatment of inflammatory diseases including hidradenitis suppurativa, psoriatic arthritis, palmoplantar pustulosis, axial spondyloarthritis and psoriasis. Being developed for adult and adolescent patients with moderate-to-severe inflammatory conditions.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-21
Description

Manufacturing partnership with Vetter Pharma International GmbH to support commercialization of sonelokimab. Vetter will provide fill-finish and manufacturing capabilities for the drug product.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-05-01
Description

License agreement announced in May 2021 for global rights to sonelokimab (M1095/ALX-0761). Terms included USD 25m upfront payment plus 9.9% ownership stake to Merck KGaA, with royalties in the low teens.

Strategic tierCoreTypeTechnology or Integration
Description

Nanobody technology IP licensed from Ablynx. The terms Nanobody and Nanobodies are trademarks of Ablynx, a Sanofi company. MoonLake's sonelokimab is based on this technology platform.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UCB's Bimzelx (bimekizumab) is the only other approved IL-17A/F dual inhibitor and is approved for HS in major markets, making it the most direct head-to-head competitor to sonelokimab in inflammatory skin and joint diseases.

TypeBroad incumbent
Description

Novartis markets Cosentyx (secukinumab), the leading IL-17A inhibitor across psoriasis, PsA, axSpA, and HS — the established incumbent that sonelokimab must displace in these inflammatory indications.

TypeBroad incumbent
Description

Eli Lilly's Taltz (ixekizumab) is a leading IL-17A antibody approved for plaque psoriasis, PsA, axSpA, and HS — a broad incumbent competing in the same IL-17 dermatology/rheumatology indications as MoonLake.

TypeBroad incumbent
Description

Sanofi's Dupixent (dupilumab) is the dominant biologic for HS and atopic dermatitis via IL-4/13 inhibition. As the parent of Ablynx (Nanobody licensor) and operator of an HS franchise, Sanofi is both a strategic counterparty and competitor to MoonLake.

TypeBroad incumbent
Description

AbbVie's Skyrizi (risankizumab, IL-23) and Rinvoq (upadacitinib, JAK) are major competitors across psoriasis, PsA, and HS, and set the formulary and pricing benchmarks MoonLake will face at launch.

TypeBroad incumbent
Description

J&J's Tremfya (guselkumab, IL-23) competes in moderate-to-severe HS, psoriasis, and PsA, and represents one of the established biologic alternatives physicians may choose over sonelokimab.

7Bristol-Myers Squibb
TypeBroad incumbent
Description

BMS's Sotyktu (deucravacitinib, TYK2 inhibitor) is an oral competitor in psoriasis and PsA and represents an alternative mechanism that dermatologists/rheumatologists may prefer over injectable IL-17 biologics.

TypeEmerging player
Description

Arcutis is a US dermatology-focused commercial-stage biotech with topical and systemic treatments for psoriasis and atopic dermatitis; it competes for the same dermatology prescribing audience and payer access that sonelokimab targets.

TypeEmerging player
Description

AnaptysBio develops cytokine-targeted antibodies (including IL-17 and IL-23 programs) and is a smaller, emerging immunology biotech whose pipeline overlaps with MoonLake's IL-17A/F and broader inflammatory disease strategy.

TypeRegional player
Description

Almirall is a European dermatology specialty pharma with a portfolio in psoriasis, atopic dermatitis, and HS — a regional incumbent operating in MoonLake's EMEA home market with overlapping therapeutic areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MoonLake Immunotherapeutics

Biopharmaceuticals for inflammatory diseasesmoonlaketx.com

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab, a trivalent Nanobody that inhibits IL-17A and IL-17F, for inflammatory skin and joint diseases including hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis, with first commercial launch targeted for H2 2027.

What MoonLake Immunotherapeutics does

MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company founded in 2021 and domiciled in Zug, Switzerland, listed on Nasdaq under ticker MLTX via De-SPAC in April 2022. The company is developing sonelokimab (SLK), a novel ~40 kDa trivalent humanized Nanobody — built from three covalently linked VHH domains — that simultaneously inhibits IL-17A/A, IL-17A/F, and IL-17F/F dimers while an albumin-binding domain enriches the molecule at sites of inflammatory edema. This mechanism, combined with the small size of the Nanobody format versus ~150 kDa traditional antibodies, is positioned to deliver deeper tissue penetration in difficult-to-reach inflamed sites. The technology platform and sonelokimab itself were in-licensed from Merck KGaA (global rights, $25M upfront plus 9.9% equity, low-teens royalties), with the underlying Nanobody IP held by Ablynx (Sanofi).

The company targets inflammatory diseases driven by IL-17 dysregulation across dermatology and rheumatology, with an active pipeline including Phase 3 VELA-1 and VELA-2 (hidradenitis suppurativa, 838 patients across 8+ countries), Phase 3 VELA-TEEN (adolescent HS), Phase 3 IZAR-1 and IZAR-2 (psoriatic arthritis), Phase 2 S-OLARIS (axial spondyloarthritis, 81% ASAS40 at Week 12), Phase 2 P-OLARIS, and Phase 2 LEDA (palmoplantar pustulosis, FDA Fast Track granted). Leadership includes former McKinsey Senior Partner Jorge Santos da Silva as CEO and Kristian Reich as Founder/CSO. The company is pre-revenue with operating losses of approximately -$267M TTM and a cash position of $357.9M-$394M as of late 2025/early 2026, supported by over $905M in cumulative funding. A BLA for sonelokimab in HS is planned for September 2026 following a positive FDA pre-BLA meeting in May 2026, with US commercial launch targeted for H2 2027 via field sales, specialty pharmacy distribution, and patient hub services supported by a Vetter Pharma manufacturing partnership.

MoonLake Immunotherapeutics firmographics

Firmographics
Name
MoonLake Immunotherapeutics
Legal name
MoonLake Immunotherapeutics AG
Website
https://moonlaketx.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
101–250 employees
Short description
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab, a trivalent Nanobody that inhibits IL-17A and IL-17F, for inflammatory skin and joint diseases including hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis, with first commercial launch targeted for H2 2027.
Ownership category
akta.pro rank

MoonLake Immunotherapeutics industry classification

Industry
Product category
Biopharmaceuticals for inflammatory diseases
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Nanobody therapeutics
  • Inflammatory disease treatments
  • IL-17 inhibitors
  • Clinical-stage biopharmaceuticals
  • Dermatology and rheumatology drugs

Where MoonLake Immunotherapeutics is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

MoonLake Immunotherapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage company. Expects first commercial launch in the United States in the second half of 2027 if sonelokimab is approved for hidradenitis suppurativa. Revenue will come from product sales of sonelokimab targeting inflammatory diseases.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

MoonLake Immunotherapeutics product offering

Product offering

Core offering

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab (SLK), a novel ~40 kDa trivalent Nanobody that simultaneously inhibits IL-17A and IL-17F cytokines and binds human albumin to concentrate at inflamed tissues. The product candidate is being advanced through Phase 3 trials for hidradenitis suppurativa (VELA program) and psoriatic arthritis (IZAR program), with Phase 2 programs in palmoplantar pustulosis (LEDA, FDA Fast Track) and axial spondyloarthritis (S-OLARIS).

Product overview

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing a pipeline of next-level Nanobody® treatments for inflammatory diseases. The company's core product is sonelokimab (SLK), a novel ~40 kDa humanized Nanobody® targeting IL-17A and IL-17F cytokines. The therapeutic portfolio spans dermatology indications (hidradenitis suppurativa, psoriasis, palmoplantar pustulosis) and rheumatology indications (psoriatic arthritis, axial spondyloarthritis). The clinical pipeline includes multiple Phase 3 programs (VELA for HS, IZAR for PsA), Phase 2 trials (S-OLARIS for axSpA, LEDA for PPP), and Phase 3 ready development for psoriasis. The Nanobody® platform technology enables enhanced tissue penetration and targeted inhibition of inflammatory pathways compared to traditional antibodies.

Differentiator

Problem solved

Functional benefit

Brands

  • SPARK Programme: Dynamic paid traineeship programme designed to give candidates hands-on experience in the biotech industry over 3 to 12 months, with opportunities in HR, Tech Ops, Medical Affairs, Clinical Operations, and other areas across Zug, Cambridge, and Porto offices.

Products and services

  • Sonelokimab (SLK / M1095 / ALX-0761) Novel ~40 kDa humanized trivalent Nanobody therapeutic candidate that selectively binds IL-17A and IL-17F (inhibiting IL-17A/A, IL-17A/F and IL-17F/F dimers) and human serum albumin, intended for the treatment of inflammatory diseases including hidradenitis suppurativa, psoriatic arthritis, palmoplantar pustulosis, axial spondyloarthritis and psoriasis. Being developed for adult and adolescent patients with moderate-to-severe inflammatory conditions.

Quantifiable outcome

  • 67.2% HiSCR75 response rate at Week 52 in HS Phase 3 VELA trials
  • +6 more outcomes

Companies that use MoonLake Immunotherapeutics

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

MoonLake Immunotherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

MoonLake Immunotherapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Vetter Pharma International GmbHcoreStrategic or Co-development Partner · 21 June 2026Manufacturing partnership with Vetter Pharma International GmbH to support commercialization of sonelokimab. Vetter will provide fill-finish and manufacturing capabilities for the drug product.
  • Merck KGaAcoreOEM/ Whitelabel/ Licensing Partner · 1 May 2021License agreement announced in May 2021 for global rights to sonelokimab (M1095/ALX-0761). Terms included USD 25m upfront payment plus 9.9% ownership stake to Merck KGaA, with royalties in the low teens.
  • Ablynx (Sanofi company)coreTechnology or IntegrationNanobody technology IP licensed from Ablynx. The terms Nanobody and Nanobodies are trademarks of Ablynx, a Sanofi company. MoonLake's sonelokimab is based on this technology platform.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

MoonLake Immunotherapeutics competitors and assessment

Company assessment

Direct peers

  • UCB: UCB's Bimzelx (bimekizumab) is the only other approved IL-17A/F dual inhibitor and is approved for HS in major markets, making it the most direct head-to-head competitor to sonelokimab in inflammatory skin and joint diseases.

Broad incumbents

  • Novartis: Novartis markets Cosentyx (secukinumab), the leading IL-17A inhibitor across psoriasis, PsA, axSpA, and HS — the established incumbent that sonelokimab must displace in these inflammatory indications.
  • Eli Lilly: Eli Lilly's Taltz (ixekizumab) is a leading IL-17A antibody approved for plaque psoriasis, PsA, axSpA, and HS — a broad incumbent competing in the same IL-17 dermatology/rheumatology indications as MoonLake.
  • Sanofi: Sanofi's Dupixent (dupilumab) is the dominant biologic for HS and atopic dermatitis via IL-4/13 inhibition. As the parent of Ablynx (Nanobody licensor) and operator of an HS franchise, Sanofi is both a strategic counterparty and competitor to MoonLake.
  • AbbVie: AbbVie's Skyrizi (risankizumab, IL-23) and Rinvoq (upadacitinib, JAK) are major competitors across psoriasis, PsA, and HS, and set the formulary and pricing benchmarks MoonLake will face at launch.
  • Johnson & Johnson: J&J's Tremfya (guselkumab, IL-23) competes in moderate-to-severe HS, psoriasis, and PsA, and represents one of the established biologic alternatives physicians may choose over sonelokimab.
  • Bristol-Myers Squibb: BMS's Sotyktu (deucravacitinib, TYK2 inhibitor) is an oral competitor in psoriasis and PsA and represents an alternative mechanism that dermatologists/rheumatologists may prefer over injectable IL-17 biologics.

Emerging players

  • Arcutis Biotherapeutics: Arcutis is a US dermatology-focused commercial-stage biotech with topical and systemic treatments for psoriasis and atopic dermatitis; it competes for the same dermatology prescribing audience and payer access that sonelokimab targets.
  • AnaptysBio: AnaptysBio develops cytokine-targeted antibodies (including IL-17 and IL-23 programs) and is a smaller, emerging immunology biotech whose pipeline overlaps with MoonLake's IL-17A/F and broader inflammatory disease strategy.

Regional players

  • Almirall: Almirall is a European dermatology specialty pharma with a portfolio in psoriasis, atopic dermatitis, and HS — a regional incumbent operating in MoonLake's EMEA home market with overlapping therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

MoonLake Immunotherapeutics social profiles

Digital presence

MoonLake Immunotherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MoonLake Immunotherapeutics leadership team

Management profile

Number of profiles

Profiles15 records

MoonLake Immunotherapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MoonLake Immunotherapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MoonLake Immunotherapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MoonLake Immunotherapeutics

What does MoonLake Immunotherapeutics do?

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab (SLK), a novel ~40 kDa trivalent Nanobody that simultaneously inhibits IL-17A and IL-17F cytokines and binds human albumin to concentrate at inflamed tissues. The product candidate is being advanced through Phase 3 trials for hidradenitis suppurativa (VELA program) and psoriatic arthritis (IZAR program), with Phase 2 programs in palmoplantar pustulosis (LEDA, FDA Fast Track) and axial spondyloarthritis (S-OLARIS).

Is MoonLake Immunotherapeutics a public or private company?

MoonLake Immunotherapeutics is a public company. It is classified as public and is currently operating.

When was MoonLake Immunotherapeutics founded?

MoonLake Immunotherapeutics was founded in 2021. It employs 101 to 250 people.

Where is MoonLake Immunotherapeutics based?

MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, in the Europe region.

How does MoonLake Immunotherapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are MoonLake Immunotherapeutics's main competitors?

UCB is listed as a direct peer. Broad incumbents are Novartis, Eli Lilly, Sanofi, AbbVie, Johnson & Johnson and Bristol-Myers Squibb. Emerging players are Arcutis Biotherapeutics and AnaptysBio. Almirall is listed as a regional player.

Does MoonLake Immunotherapeutics have an API?

No public API is recorded for MoonLake Immunotherapeutics.

What industry is MoonLake Immunotherapeutics in?

MoonLake Immunotherapeutics's product category is Biopharmaceuticals for inflammatory diseases. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StocktwitsMLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug FilingMoonLake Immunotherapeutics' stock rose on optimism ahead of the FDA acceptance deadline for its lead drug filing. The company is developing Sonelokimab primarily for hidradenitis suppurativa, a chronic inflammatory skin condition with limited effective treatments.TradingViewMLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug FilingMoonLake Immunotherapeutics shares rose about 8% after submitting a Biologics License Application for sonelokimab to the FDA on September 30. Acceptance is expected before November's end, with a decision on Priority Review. The company plans commercialization in HS in the second half of 2027.Business & FinancialMLTX Stock Climbs On Optimism Ahead Of FDA Acceptance Deadline For Lead Drug FilingMoonLake Immunotherapeutics shares rose about 8% after submitting a Biologics License Application for sonelokimab to the FDA on September 30. The company expects acceptance before November's end, with pooled VELA trial data showing 67.2% of HS patients achieving a 75% reduction in lesions. Commercialization in HS is targeted for the second half of 2027.Simply Wall StMoonLake Immunotherapeutics (MLTX) Reports Wider Net Loss, Is It Still Below Fair Value?MoonLake Immunotherapeutics reported Q3 2026 results with a wider net loss, though loss per share narrowed year-over-year. Shares fell 27.10% over 90 days to $12.56, while analyst fair value is $28.54, implying undervaluation. Management cites 2.9 million U.S. hidradenitis suppurativa patients, only 3% on biologics, as a potential revenue growth driver.YahooMoonLake Immunotherapeutics Stock In Focus After Quarterly Loss UpdateMoonLake Immunotherapeutics reported a Q3 2026 net loss of $79.55 million and a nine-month loss of $211.06 million, with loss per share narrowing year-over-year. The company plans a BLA submission for hidradenitis suppurativa by end of Q3 2026, with revenue and earnings projections of $289.4 million and $49.9 million by 2029.American City Business JournalsMoonLake Immunotherapeutics taps Miami for U.S. headquartersMoonLake Immunotherapeutics is moving its U.S. headquarters to Miami, with the location expected to accommodate up to 75 employees, including some new local hires. The company is publicly traded.MarketScreenerMoonLake Immunotherapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026MoonLake Immunotherapeutics reported a nine-month net loss of USD 211.06 million, up from USD 164.89 million a year earlier. Basic and diluted loss per share from continuing operations were USD 2.74 each, compared to USD 2.61 a year ago.Seeking AlphaMoonLake Immunotherapeutics GAAP EPS of -$0.93 misses by $0.15 (MLTX:NASDAQ)MoonLake Immunotherapeutics reported Q3 GAAP EPS of -$0.93, missing by $0.15. The company ended the quarter with $498.5 million in cash and expects a runway to mid-2028, with up to $400 million available through its Hercules Capital debt facility.TradingViewMoonLake Reports Q3 2026 Results, $498.5 Million in CashMoonLake reported a Q3 2026 net loss of $79.5 million and ended September with $498.5 million in cash. R&D expenses rose to $68.9 million, and the company expects its cash runway to extend to mid-2028. It also expects to begin enrollment in the Phase 3 NOVA trial in November 2026.TradingViewMLTX: FDA BLA submitted for SLK as $498.5M in liquidity funds development toward mid-2028MoonLake Immunotherapeutics submitted the FDA BLA for SLK in HS, targeting a U.S. launch in H2 2027 if approved. Q3 net loss widened to $79.5M as operating expenses increased, while $498.5M in cash and investments support a mid-2028 runway.